NewAmsterdam Pharma Co N.V. (NAMS) — Shareholders' Equity
| Fiscal Year | Shareholders' Equity | Change YoY |
|---|---|---|
| 2025 | $683.43M | -9.8% |
| 2024 | $757.50M | +162.7% |
| 2023 | $288.39M | -32.9% |
| 2022 | $430.07M | +477.9% |
| 2021 | -$113.82M | -55.8% |
| 2020 | -$73.03M | — |
| Fiscal Year | Shareholders' Equity | Change YoY |
|---|---|---|
| 2025 | $683.43M | -9.8% |
| 2024 | $757.50M | +162.7% |
| 2023 | $288.39M | -32.9% |
| 2022 | $430.07M | +477.9% |
| 2021 | -$113.82M | -55.8% |
| 2020 | -$73.03M | — |